Abstract 24TiP
Background
A high-risk subpopulation of ER+/HER2− breast cancer (BC) is characterized by high-grade tumors, decreased sensitivity to endocrine therapy (ET), higher responsiveness to chemotherapy (CT), and worse prognosis. Prior studies suggest that increased pathological complete response (pCR) rates after neoadjuvant CT may have a substantial impact for patients with high-risk, early-stage, HR+/HER2− BC. KEYNOTE-756 (NCT03725059) is a global, randomized, double-blind, phase 3 study of pembrolizumab (vs placebo) + CT as neoadjuvant treatment followed by pembrolizumab (vs placebo) + ET as adjuvant treatment for patients with high-risk, early-stage, ER+/HER2− BC.
Trial design
Patients with T1c-2 cN1-2 (tumor size ≥2 cm) or T3-4 cN0-2 grade 3, invasive, ductal ER+/HER2− BC will be stratified by lymph node involvement (positive vs negative), tumor PD-L1 status (positive [CPS ≥1] vs negative [CPS <1]), ER positivity (ER + ≥10% vs ER + <10%), and anthracycline dosing schedule (every 3 weeks [Q3W] vs Q2W), then randomized 1:1 to neoadjuvant treatment with pembrolizumab 200 mg Q3W or placebo combined with paclitaxel (80 mg/m2 Q1W) for 4 cycles followed by doxorubicin (60 mg/m2) or epirubicin (100 mg/m2), each with cyclophosphamide (600 mg/m2) Q2/3W for 4 cycles. After definitive surgery (± radiation therapy, as indicated), patients will receive adjuvant treatment of pembrolizumab (200 mg Q3W) or placebo for 9 more administrations combined with ET, which can be given for up to 10 years. No crossover between treatment cohorts when moving from neoadjuvant to adjuvant treatment is allowed. Dual primary endpoints are pCR rate (ypT0/Tis ypN0) and event-free survival (EFS). Secondary endpoints include ypT0/Tis and ypT0 ypN0 pCR rates in all patients and all 3 pCR definitions in those with PD-L1+ tumors, EFS in patients with PD-L1+ tumors, overall survival, safety, and health-related quality of life. Enrollment is currently ongoing in 22 countries around the world, including Korea, Taiwan, China, and Japan.
Clinical trial identification
NCT03725059.
Legal entity responsible for the study
Merck & Co., Inc.
Funding
Funding for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
F. Cardoso: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas/Medivation; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Celgene; Advisory / Consultancy: Daiichi-Sankyo; Advisory / Consultancy: Eisai; Advisory / Consultancy: GE Oncology; Advisory / Consultancy: Genentech; Advisory / Consultancy: GlaxoSmithKline; Advisory / Consultancy: Macrogenics; Advisory / Consultancy: Medscape; Advisory / Consultancy: Merck-Sharp; Advisory / Consultancy: Merus BV; Advisory / Consultancy: Mylan; Advisory / Consultancy: Mundipharma GmbH; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Pierre-Fabre; Advisory / Consultancy: prIME Oncology; Advisory / Consultancy: Roche. A. Bardia: Advisory / Consultancy, Research grant / Funding (self): bioTheranostics; Advisory / Consultancy: Genentech; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Immunomedics; Advisory / Consultancy: Innocrin Pharmaceuticals; Advisory / Consultancy: Merck; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Radius Health; Advisory / Consultancy: Radius Pharma; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Spectrum Pharmaceuticals. F. André: Research grant / Funding (institution): Novartis; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Roche. D.W. Cescon: Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Genomic Health; Advisory / Consultancy, Research grant / Funding (institution): GlaxoSmithKline; Advisory / Consultancy, Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche/Genentech. H. McArthur: Advisory / Consultancy: Celgene; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy: OBI Pharma; Advisory / Consultancy: Roche; Advisory / Consultancy: Spectrum Pharmaceuticals; Advisory / Consultancy: Syndax Pharmaceuticals; Advisory / Consultancy: Peregrine; Advisory / Consultancy: Calithera; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): Eli Lilly; Research grant / Funding (self): MedImmunne; Research grant / Funding (self): LLC/AstraZeneca. M. Telli: Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Genentech; Advisory / Consultancy: Aduro; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: Immunomedics; Advisory / Consultancy: Celldex; Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): OncoSec; Research grant / Funding (institution): Biothera; Research grant / Funding (institution): Vertex; Research grant / Funding (institution): Calithera; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): PharmaMar. S. Loi: Advisory / Consultancy: AstraZeneca/MedImmune; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy: Seattle Genetics; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Puma Biotechnology. J. Cortes: Shareholder / Stockholder / Stock options: MedSIR; Honoraria (self), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Eisai; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self): Samsung; Advisory / Consultancy: Cellestia Biotech; Advisory / Consultancy, Research grant / Funding (institution): AstaZeneca; Advisory / Consultancy: Biothera; Advisory / Consultancy: Merus; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Daiichi-Sankyo; Advisory / Consultancy: ERYTECH Pharma; Advisory / Consultancy: Polyphor; Research grant / Funding (institution): ARIAD; Research grant / Funding (institution): Baxalta GmbH; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Guardant Health; Research grant / Funding (institution): Merck. P. Schmid: Full / Part-time employment: Roche; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Bayer; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Celgene; Honoraria (self): Eisai; Honoraria (self), Research grant / Funding (institution): Genentech/Roche; Honoraria (self), Research grant / Funding (institution): Merck; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self): Pfizer; Honoraria (self): Puma Biotechnology; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): Oncogenex. N. Harbeck: Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer. C. Denkert: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Teva; Honoraria (self): Roche; Shareholder / Stockholder / Stock options: Sividon Diagnostics; Advisory / Consultancy: Daiichi-Sankyo; Advisory / Consultancy: MSD Oncology; Licensing / Royalties, patent application—therapy response: EP20150702464; Licensing / Royalties, patent application— cancer immunotherapy: EP18209672; Licensing / Royalties, digital pathology software: VMScope. C. Jackisch: Honoraria (self), Advisory / Consultancy: Merck. L. Jia: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck. K. Hirshfield: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck. V. Karantza: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck.
Resources from the same session
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract